Ensysce Biosciences Inc

ENSC

Company Profile

  • Business description

    Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

  • Contact

    7946 Ivanhoe Avenue
    Suite 201
    La JollaCA92037
    USA

    T: +1 858 263-4196

    https://www.ensysce.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    8

Stocks News & Analysis

stocks

Weekly Earnings Wrap: CBA, CSL, MQG and more

Everything you need to know on last weeks earnings results
stocks

ASX player rallies on small guidance upgrade

Our fair value is maintained despite investor enthusiasm.
stocks

After earnings, is Alphabet stock a buy, a sell, or fairly valued?

With strong fourth-quarter earnings and AI integration, here’s what we think of Alphabet stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,138.8045.70-0.50%
CAC 408,311.7428.82-0.35%
DAX 4024,914.8862.190.25%
Dow JONES (US)49,500.9348.950.10%
FTSE 10010,446.3543.910.42%
HKSE26,567.12616.03-2.27%
NASDAQ22,546.6750.48-0.22%
Nikkei 22556,941.97708.57-1.23%
NZX 50 Index13,198.18248.19-1.85%
S&P 5006,836.173.410.05%
S&P/ASX 2008,917.601.600.02%
SSE Composite Index4,082.0751.95-1.26%

Market Movers